EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer

Benjamin N Christopher iD, Lena Golick iD, Ashton Basar, Leticia Reyes, Reeder M Robinson, Aaron O Angerstein iD, Carsten Krieg, G Aaron Hobbs iD, Denis C Guttridge, John P O'Bryan, Nathan G Dolloff

Biomolecules · 2025

DOI: 10.3390/biom15050645 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Benjamin N Christopher und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA. Hauptthemen laut MEDLINE: Receptors, Interleukin-8B, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Recombinant Fusion Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute (NCI) of the National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest 5-year survival rates of all cancers, and limited treatment options exist. Immunotherapy is effective in some cancer types, but the immunosuppressive tumor microenvironment (TME) of PDAC is a barrier to effective immunotherapy. CXCR2+ myeloid-derived suppressor cells (MDSCs) are abundant in PDAC tumors in humans and in mouse models. MDSCs suppress effector cell function, making them attractive targets for restoring anti-tumor immunity. In this study, we show that the most abundant soluble factors released from a genetically diverse set of human and mouse PDAC cells are CXCR2 ligands, including CXCL8, CXCL5, and CXCL1. Expression of CXCR2 ligands is at least partially dependent on mutant KRAS and NFκB signaling, which are two of the most commonly dysregulated pathways in PDAC. We show that MDSCs are the most prevalent immune cells in PDAC tumors. MDSCs expressed high levels of CXCR2, and we found that myeloid cells readily migrate toward conditioned media (CM) prepared from PDAC cultures. We designed CXCR2 ligand-Fc fusion proteins to modulate the CXCR2 chemotactic signaling axis. Unexpectedly, these fusion proteins were superior to native chemokines in binding and activation of CXCR2 on myeloid cells. These “superkines” were potent inhibitors of PDAC CM-induced myeloid cell migration and were superior to CXCR2 small-molecule inhibitors and neutralizing antibodies. Our findings suggest that CXCR2 superkines may disrupt myeloid cell recruitment to PDAC tumors, ultimately improving immunotherapy outcomes in patients with PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Interleukin-8BPancreatic NeoplasmsCarcinoma, Pancreatic DuctalRecombinant Fusion ProteinsChemokinesHumansAnimalsMiceSignal TransductionCell Line, TumorTumor MicroenvironmentMyeloid-Derived Suppressor CellsMyeloid CellsChemokine CXCL1

Stichwörter der Autor:innen

CXCL1CXCR2MDSCsimmunosuppressionmyeloid cell migrationpancreatic ductal adenocarcinomatumor microenvironment

Substanzen

Receptors, Interleukin-8BCXCR2 protein, humanRecombinant Fusion ProteinsChemokinesChemokine CXCL1

Autor:innen und Institutionen

  • Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA.
  • Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
  • Department of Biochemistry, Medical University of South Carolina, Charleston, SC 29425, USA.
  • MUSC Hollings Cancer Center, Charleston, SC 29425, USA.
  • MUSC Darby Children's Research Institute, Charleston, SC 29425, USA.
  • Department of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, USA.

ORCID-Profile: Benjamin N Christopher, Lena Golick, Aaron O Angerstein, G Aaron Hobbs

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Cancer Institute (NCI) of the National Institutes of Health (NIH)
  • Hollings Cancer Center Team Science Award

Zitieren

APA

Christopher, B. N., Golick, L., Basar, A., Reyes, L., Robinson, R. M., Angerstein, A. O., Krieg, C., Hobbs, G. A., Guttridge, D. C., O'Bryan, J. P., & Dolloff, N. G. (2025). Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer. Biomolecules. https://doi.org/10.3390/biom15050645

Vancouver

Christopher BN, Golick L, Basar A, Reyes L, Robinson RM, Angerstein AO, et al. Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer. Biomolecules. 2025. doi:10.3390/biom15050645

BibTeX
@article{Christopher2025,
  author = {Christopher, Benjamin N and Golick, Lena and Basar, Ashton and Reyes, Leticia and Robinson, Reeder M and Angerstein, Aaron O and Krieg, Carsten and Hobbs, G Aaron and Guttridge, Denis C and O'Bryan, John P and Dolloff, Nathan G},
  title = {Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15050645}
}
Kostenlos starten →